Department of Biology, Faculty of Science, Istanbul University, Vezneciler, Istanbul 34459, Turkey.
Faculty of Pharmacy, Marmara University, Haydarpaşa, Istanbul 34668, Turkey.
Oncol Rep. 2018 Jul;40(1):527-535. doi: 10.3892/or.2018.6364. Epub 2018 Apr 12.
In the present study, the in vitro cytotoxic effect of poly(ADP‑ribose) polymerase (PARP) inhibitor alone and in combination with nab‑paclitaxel was evaluated on human triple‑negative breast cancer (TNBC) cell line MDA‑MB‑231 and human luminal A breast cancer cell line MCF‑7. For this purpose, cell index (CI) values obtained from xCELLigence Real‑Time Cell Analysis (RTCA) DP instrument, mitotic index (MI), labelling index (LI) and apoptotic index (AI) analysis among cell kinetic parameters were used. As a result of PARP inhibitor application, there was a significant decrease in CI, MI and LI and a significant increase in AI for all the experimental groups. After application of PARP inhibitor in combination with nab‑paclitaxel, the CI values were decreased for both cell lines, and the differences between the control and all the experimental groups were statistically significant (P<0.01) for all applications. PARP inhibitor, alone or in combination with nab‑paclitaxel offers a promising treatment modality in different breast cancer subtypes.
在本研究中，评估了聚（ADP-核糖）聚合酶（PARP）抑制剂单独及联合奈达铂紫杉醇对人三阴性乳腺癌（TNBC）细胞系 MDA-MB-231 和人腔上皮型乳腺癌细胞系 MCF-7 的体外细胞毒性作用。为此，使用实时细胞分析（RTCA） DP 仪器获得的细胞指数（CI）值、有丝分裂指数（MI）、标记指数（LI）和细胞动力学参数中的细胞凋亡指数（AI）进行分析。PARP 抑制剂应用后，所有实验组的 CI、MI 和 LI 均显著下降，AI 显著升高。PARP 抑制剂联合奈达铂紫杉醇应用后，两种细胞系的 CI 值均下降，所有应用中对照组与所有实验组之间的差异均具有统计学意义（P<0.01）。PARP 抑制剂单独或联合奈达铂紫杉醇为不同乳腺癌亚型提供了一种有前途的治疗方式。
